Atorvastatin + Ezetimibe + ASA
Benefits at a glance
- Lifecycle management for Atorvastatin + Ezetimibe combination.
- High perecentage of the Atorvastanin + Ezetemibe patients are already treated with Acetylsalicylic acid (ASA) (baseline treatment).
Product details
Indication
Strengths
40mg + 10mg + 100mg
80mg + 10mg + 100mg
Dosage form
API
Regulatory approach
Substitution of the triple monosubstances
Dossier available
Turnover
Development by
Summary
With our new fixed dose combination, we have combined three established active ingredients used for the treatment of Dyslipidemia.
Our triple combination of Atorvastatin + Ezetimibe + ASA is a logical lifecycle addition to the already existing combination of Atorvastatin + Ezetimibe.
It delivers the required medication while reducing the number of single tablets patients need to take. This improves improves patients compliance and quality of life in the long term.
Your Contact
Heike Sagi
Business Development & Licensing
Senior Director
Rheinstraße 49
55218 Ingelheim
Germany
-
Disclaimer
The exploitation, including the development, sale and offer for sale of products and related processes is performed by Midas only in those territories where permissible by applicable patent law in particular, but not limited to EC Directive 2001/83 EC, Article 10, as amended by EC Directive 2004/27 EC. This document, therefore, does not and shall not constitute an offer for sale for the product in territories where an offer for sale or sale is not permissible by law. Midas expressly disclaims any liability for the information provided in this document as well as for damages resulting from or arising out of the use of the product and related process for purposes other than research and development in compliance with applicable laws.